ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
132.190,64
0,18%
S&P 500
5.667,56
0,08%
US Dollar vs BRL
5,7209
0,80%
Bitcoin
83.966,77
-0,20%
Brent Oil
71,745
-0,17%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. BioXcel Therapeutics Inc (BTAI)

  7. BioXcel Therapeutics Inc (BTAI) Notícias

BTAI

BioXcel Therapeutics (BTAI)

BioXcel Therapeutics Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:BTAI
DataHoraFonteTítuloCódigoCompanhia
21/03/202508:00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:BTAIBioXcel Therapeutics Inc
17/03/202519:37Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
11/03/202508:00GlobeNewswire Inc.BioXcel Therapeutics Strengthens Cash Position to Advance SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
07/03/202509:00GlobeNewswire Inc.BioXcel Therapeutics Announces 33% Enrollment in SERENITY At-Home Pivotal Phase 3 Safety Trial for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
04/03/202518:15GlobeNewswire Inc.BioXcel Therapeutics Announces Closing of $14 Million Registered Direct OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
04/03/202510:51Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:BTAIBioXcel Therapeutics Inc
03/03/202517:33GlobeNewswire Inc.BioXcel Therapeutics Announces $14 Million Registered Direct OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
03/03/202509:00GlobeNewswire Inc.BioXcel Therapeutics Announces FDA Closed its Inspection of Site for Phase 3 TRANQUILITY II Trial for Acute Treatment of Agitation Associated with Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
28/02/202509:00GlobeNewswire Inc.BioXcel Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RuleNASDAQ:BTAIBioXcel Therapeutics Inc
06/02/202509:00GlobeNewswire Inc.BioXcel Therapeutics Announces Reverse Stock SplitNASDAQ:BTAIBioXcel Therapeutics Inc
05/02/202509:00GlobeNewswire Inc.BioXcel Therapeutics Provides Clinical and Business UpdateNASDAQ:BTAIBioXcel Therapeutics Inc
21/01/202502:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:BTAIBioXcel Therapeutics Inc
10/01/202518:45Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:BTAIBioXcel Therapeutics Inc
30/12/202418:15Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:BTAIBioXcel Therapeutics Inc
18/12/202419:16Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:BTAIBioXcel Therapeutics Inc
16/12/202417:59Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:BTAIBioXcel Therapeutics Inc
22/11/202410:16GlobeNewswire Inc.BioXcel Therapeutics Announces Pricing of $7.0 Million Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
21/11/202418:47GlobeNewswire Inc.BioXcel Therapeutics Announces Proposed Public OfferingNASDAQ:BTAIBioXcel Therapeutics Inc
14/11/202411:10Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:BTAIBioXcel Therapeutics Inc
14/11/202409:00GlobeNewswire Inc.BioXcel Therapeutics Reports Third Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
12/11/202409:00GlobeNewswire Inc.BioXcel Therapeutics Advances Pivotal Phase 3 Trials of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders, Schizophrenia, and Alzheimer’s DementiaNASDAQ:BTAIBioXcel Therapeutics Inc
08/11/202409:00GlobeNewswire Inc.BioXcel Therapeutics to Report Third Quarter 2024 Financial Results on November 14, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
29/10/202408:00GlobeNewswire Inc.BioXcel Therapeutics to Present at ThinkEquity ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
15/10/202408:00GlobeNewswire Inc.BioXcel Therapeutics Announces U.S. Department of Defense Grant to University of North Carolina to Fund Study of BXCL501 (Sublingual Dexmedetomidine) for Treating Acute Stress DisorderNASDAQ:BTAIBioXcel Therapeutics Inc
19/09/202408:00GlobeNewswire Inc.BioXcel Therapeutics Announces Clinical Prioritization and Update on BXCL501 Late-Stage Programs for AgitationNASDAQ:BTAIBioXcel Therapeutics Inc
17/09/202420:17Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:BTAIBioXcel Therapeutics Inc
05/09/202408:00GlobeNewswire Inc.BioXcel Therapeutics Announces Initiation of SERENITY At-Home Pivotal Phase 3 Safety Trial of BXCL501 for Acute Treatment of Agitation Associated with Bipolar Disorders or SchizophreniaNASDAQ:BTAIBioXcel Therapeutics Inc
07/08/202408:00GlobeNewswire Inc.BioXcel Therapeutics to Participate in Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:BTAIBioXcel Therapeutics Inc
06/08/202408:00GlobeNewswire Inc.BioXcel Therapeutics Reports Second Quarter 2024 Financial ResultsNASDAQ:BTAIBioXcel Therapeutics Inc
30/07/202408:00GlobeNewswire Inc.BioXcel Therapeutics to Report Second Quarter 2024 Financial Results on August 6, 2024NASDAQ:BTAIBioXcel Therapeutics Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:BTAI

Seu Histórico Recente

EU
AFRHU
Amundi Luxembourg
NASDAQ
ABMHJXX
Morgan Stanley Finance L...
TSXV
RMG
Rainmaker Resources Ltd.
BFNX
ETHUSD
Ethereum
TG
MFJ
Polynovo
LSE
GCOR
Frk Sus Grc Etf
EU
BCART
Biocartis Group NV
BOV
JSLG3
JSL ON
LSE
PT29
Adnoc Mur. 34s
GATE
MCASHUSDT
MCashChain
NASDAQI
PADSCNR
Benchmark Apartments and...
TSXV
VRW
LSE
HCHA
Hsbc Msci Cn Ac
BSTP
AMPEUR
Amp
LATK
ANKRBTC
Ankr Network
AMEX
DSK
ML Str Rtn Select 10
Delayed Upgrade Clock
ADVFN Logo
Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados

Vá sem anúncios

Assine uma experiência sem anúncios

Sem anúncios

Experimente agora

Manter os anúncios